Gliadel Wafers for Treatment of Brain Tumors
A biodegradable polymer 'wafer' (Gliadel - Rh ne-Poulenc Rorer) impregnated with the alkylating agent carmustine (BCNU; Bicnu) has been marketed in the USA for local treatment of recurrent glioblastoma multiforme that requires re-operation. The dime-sized polyanhydride wafers are implanted into the surgical cavity left behind after resection. Release of the alkylating agent directly into the area of the tumor bypasses the blood-brain barrier (H Brem and R Langer, Sci Med, 3:1, 1996)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Gliadel Wafers for Treatment of Brain Tumors
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1035
Article Code: 1035c
Date: September 11, 1998
Volume: 40
Page: 92
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1035
Article Code: 1035c
Date: September 11, 1998
Volume: 40
Page: 92
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)